This week’s tracker highlights a wave of financings targeting clear commercial inflection points, with companies scaling sales, expanding internationally, and advancing toward key regulatory milestones – as investors double down on sleep health, urology, ophthalmology, and neurotechnology.
ProSomnus raised $38M for CPAP alternative
ProSomnus announced that it raised $38M through a strategic investment from Catalio Capital Management. The company plans to use the funds to accelerate the global expansion of its technology-enabled sleep health platform.
With the investment, it plans to advance the development of next-generation remote patient monitoring and proprietary sleep diagnostic devices. The company also earmarked funds for comparative clinical studies and scaling infrastructure.
CEO Len Liptak
Last week’s tracker: Neurent, Aerska and more
Flinn secured $20M to develop AI tools for product lifecycle management
The round was led by HV Capital, with participation from US-based healthcare investor BHI – Bertelsmann Healthcare Investments, alongside continued support from existing investors Cherry Ventures, Speedinvest, and SquareOne.
The funding comes as healthcare systems globally face increasing pressure from ageing populations, more complex treatment approaches, and administrative challenges that are placing strain on public healthcare budgets.
Co-Founder and Co-CEO Bastian Krapinger-Rüther
Levee secured over $12M to support Voro Urologic Scaffold PMA
Levee Medical secured more than $12M in additional financing to support the premarket approval (PMA) process as the ARID II Trial of the Voro Urologic Scaffold progresses.
The proceeds will further extend the company’s financial runway and provide direct backing for the PMA after enrolment in the ARID II trial concludes. The funding round closed earlier than anticipated and was substantially oversubscribed.
CEO Adam Irving
Arbutus Medical raised C$9.3M to accelerate growth
The financing was led by Crédit Mutuel Equity, with participation from the CU Healthcare Innovation Fund, along with follow-on investments from Nimbus Synergies, ThresholdImpact, Consortium MEDTEQ+, GenomeBC, and other existing investors.
This financing follows a year of strong commercial momentum for Arbutus and positions the company to continue rapidly scaling its commercial footprint.
CEO Lawrence Buchan
Wellumio announced an A$6.2M first close of its pre-Series A round
The raise was led by Nuance Connected Capital, with support from Icehouse Ventures, NZ Growth Capital Partners (NZGCP)’s Aspire Seed Fund, Pacific Channel, Booster, and Cure Kids Ventures.
Angel investor groups Flying Kiwi and Enterprise Angels also chipped, in alongside international investors via the New Zealand Government’s Active Investor Plus (AIP) programme and retail investors through Snowball Effect.
CEO Shieak Tzeng
Synchrony Medical secured $5M to fuel commercial expansion of LibAirty System
The investment was led by Edge Medical Ventures with participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG), and angel investors.
It will accelerate U.S. commercial expansion, support ongoing clinical research and product development, and broaden patient access to LibAirty.
CEO Anat Shani
ZEISS invested in Custom Surgical to accelerate digitalization of eye health diagnostics
ZEISS Ventures participated in the €3.5M Pre-Series A financing round for Custom Surgical. The funding round, led by Ventech and joined by ZEISS along a group of other investors.
With this Pre-Series A round, Custom Surgical is poised for global expansion and advancement towards becoming the data standard for anterior segment ophthalmology, enabling improved care, outcomes, and AI-powered eye health applications.
CEO Federico Acosta
Neupulse raised £3M to accelerate delivery of neurotherapeutic technology
The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, with participation from existing and new investors.
The funding will be used to scale sales and accelerate Neupulse’s path to market, supporting product development, regulatory progress and early commercialisation, to ensure the company’s technology reaches individuals who need it most.
CEO Paul Cable
Sendance secured new funding to scale health data sensors
Sendance raised several hundred thousand euros, bringing its total funding to €2.6M. The investment is a convertible loan in the company’s ongoing third financing round.
The new investment was led by Garage Angels, a Brno-based network of experienced entrepreneurs and angel investors that supports early-stage startups with capital and hands-on expertise, with support from existing investor Electron Capital Partners.
CEO Robert Koeppe
ClotProtect secured £1.2M to tackle blood clots
The financing was raised through a combination of Innovate UK funding and angel investment from the Lifted Ventures Angel Network.
The company, which develops innovative solutions to improve patient safety and reduce the risks associated with blood clots, came through Lifted Ventures’ Elevate Her Accelerator programme.
Founder Helen Philippou
Elumn8 Medical secured a Series C funding and unveiled rebrand
The investment will be used to advance clinical development of the Acolyte image-guided crossing and re-entry catheter system, which is presently being assessed in a pre-market trial for the treatment of coronary chronic total occlusions.
The rebranding signals the company’s evolution towards advancing image-enabled technologies for coronary interventions.
CEO Joe Knight
